Scientists from the University of Leicester and the University of California Los Angeles (UCLA) have announced a major advance towards developing drugs to tackle dangerous, or 'bad', cholesterol in the body. They have filed two patents for developing targeted drugs that would act as a catalyst for lowering levels of 'bad' cholesterol. Two research papers published by the academics enhance the understanding of the regulation of low-density lipoprotein (LDL) or "bad" cholesterol. LDL, the so-called "bad" cholesterol, is often linked to medical problems like heart disease, stroke and clogged arteries. In the body, cells in the liver produce an LDL receptor that binds LDL and removes it from the blood, thereby lowering cholesterol levels. The scientists have characterised an enzyme called IDOL that plays a key role in regulating the amount of LDL receptor available to bind with 'bad' cholesterol.
Cholesterol Levels And Heart Disease Biomarkers In Diabetics Improved By Vitamin D-Fortified Yoghurt
People with diabetes are known to have an increased risk of heart disease. New research published in BioMed Central's open access journal BMC Medicine shows that regular consumption of a vitamin D-fortified yoghurt drink improves cholesterol levels and biomarkers of endothelial dysfunction, a precursor of heart disease, in diabetics. Not having enough vitamin D affects the inner lining of blood vessels (endothelial cells) eventually leading to atherosclerosis and cardiovascular disease. Endothelial dysfunction can be measured by the increased levels of a set of biomarkers, such as serum endothelin-1, E-Selectin and MMP-9. In a double-blind trial, researchers from Tehran investigated the effect of vitamin D on the glycemic status, cholesterol levels and endothelial biomarkers of diabetics.
A study using genetically modified zebrafish to visualize early events involved in development of human atherosclerosis describes an efficient model - one that the researchers say offers many applications for testing the potential effectiveness of new antioxidant and dietary therapies. The research, led by scientists from the University of California, San Diego School of Medicine, has been published online by the Journal of Clinical Investigation, and will appear in print in the December 1 issue of the journal. Atherosclerosis is a process of lipid deposition and inflammation in the artery walls. Low-density lipoprotein (LDL) that carries "bad" cholesterol in blood is easily oxidized, and oxidized LDL promotes inflammatory responses by vascular cells. Inflamed atherosclerotic plaque can often rupture;
Crestor is not significantly better at stabilizing plaque and reducing cholesterol, compared to Lipitor, a Pfizer drug that Ranbaxy Laboratories will launch in much cheaper generic versions in two weeks' time. AstraZeneca's Crestor (rosuvastatin) will be harder to sell because it is much more expensive than generic atorvastatin (Lipitor), now that no significant clinical advantage has been shown in a trial funded by AstraZeneca. Crestor's patent expires in 2016. The SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin) trial results were presented at the American Heart Association's Scientific Sessions 2011, as well as being published today in NEJM (New England Journal of Medicine. The 24-month trial, which included 1, 385 participants, led by Stephen J.
Niacin Does Not Reduce Heart Attack, Stroke Risk In Stable, Cardiovascular Patients Whose Cholesterol Is Well-Controlled To Treatment Guidelines
At the American Heart Association meeting, UB professor of medicine William E. Boden, MD, discussed the AIM-HIGH clinical trial, which found that niacin provides no incremental benefit to patients with atherosclerotic heart disease, whose levels of LDL cholesterol and non-HDL (which contributes to plaque in the arteries) were very well-controlled. In patients whose bad cholesterol is very well-controlled by statins for a long time period, the addition of high-dose, extended release niacin did not reduce the risk of cardiovascular events, including heart attack and stroke. That is the finding reported at the American Heart Association annual meeting by the study's co-principal investigator, University at Buffalo professor of medicine William E. Boden, MD; the results are also being published as the lead article the New England Journal of Medicine.